Drug intelligence / Profile preview

GKIND016A

Development stage: Preclinical
Lead developer: China Resources Guokang Pharmaceutical
Modality: Small Molecules

Overview

GKIND016A is a small molecule agonist of the 5-HT1 and 5-HT2 serotonin receptors, currently under development by China Resources Guokang Pharmaceutical. It is being investigated as a preclinical candidate for the treatment of gastrointestinal motility disorders. By targeting these serotonin receptor pathways, the compound aims to modulate the enteric nervous system and smooth muscle activity to improve gastrointestinal transit and function.

Targets

5-HT2 (5-HT2 receptor family)5-HT1R (5-HT1 receptor family)

Beyond the preview

Go deeper on GKIND016A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GKIND016A.

Explore the full profile